Commentary on "the Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics"
- PMID: 18631965
- PMCID: PMC2577814
- DOI: 10.1016/j.jalz.2008.03.003
Commentary on "the Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics"
Comment on
-
The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics.Alzheimers Dement. 2008 Mar;4(2):145-53. doi: 10.1016/j.jalz.2008.02.001. Alzheimers Dement. 2008. PMID: 18631958 Clinical Trial.
References
-
- Jones RW, Kivipelto M, Feldman H, Sparks L, Doody R, Waters D, Hey-Hadavi J, Breanza A, Schindler RJ Ramos H on behalf of the LEADe investigators. The Atorvastatin/Donepezil in Alzheimer’s Disease Study (LEADe): design and baseline characteristics. Alzheimer’s and Dementia. 2008 - PubMed
-
- Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000 Oct;57(10):1439–1443. - PubMed
-
- Dufouil C, Richard F, Fiévet N, Dartigues JF, Ritchie K, Tzourio C, Amouyel P, Alpérovitch A. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. Neurology. 2005 May 10;64(9):1531–1538. - PubMed
-
- Green RC, McNagny SE, Jayakumar P, et al. Statin use and the risk of Alzheimer’s disease: the MIRAGE stuy. Alzheimer’s and Dementia. 2006;2:96–103. - PubMed
-
- Rockwood K, Kirkland S, Hogan DB, MacKnight C, Merry H, Verreault R, Wolfson C, McDowell I. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol. 2002 Feb;59(2):223–227. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical